Prenatal Diagnosis of Fetal Arrhythmias and Assessment of Autonomic Nervous System Activity by Fetal Magnetocardiography

Akimune Fukushima1,*, Atsushi Matsumoto2, Miyuki Terata3, Tomonobu Kanasugi3 and Kenji Nakai4

1Department of Clinical Genetics, School of Medicine, Iwate Medical University, Morioka, Iwate, Japan
2Department of Pediatrics, School of Medicine, Iwate Medical University, Morioka, Iwate, Japan
3Department of Obstetrics and Gynecology, School of Medicine, Iwate Medical University, Morioka, Iwate, Japan
4Department of Dentistry and Internal Medicine, School of Dentistry, Iwate Medical University, 19-1 Uchimaru, Morioka 020-8505 Japan

Abstract: Magnetocardiography (MCG) is a technique that enables the noncontact, noninvasive measurement of electrocardiographic phenomena, and fetal magnetocardiography (FMCG) is extremely useful for the analysis of fetal electrocardiographic phenomena. We have used FMCG for the diagnosis and treatment of a range of fetal arrhythmias, and to perform comparative studies of autonomic nervous system activity in fetuses with normal growth and those with fetal growth restriction by analyzing fetal heart rate variability. In terms of fetal arrhythmias, fatal long QT syndrome was accurately diagnosed prenatally using FMCG, and pregnancy was maintained until delivery at 37 weeks gestation. With regard to fetal autonomic nervous system activity, there was a pronounced increase in sympathetic nervous activity among fetuses with normal growth in the second half of pregnancy.

Keywords: Fetus, arrhythmias, autonomic nervous system activity, fetal growth restriction, magnetocardiography, prenatal diagnosis, long QT syndrome.

1. INTRODUCTION

Appropriate assessment of fetal information is extremely important in perinatal management and treatment. Recent advances in medical electronics in fields such as ultrasonography and cardiotocography have enabled the acquisition of a wide range of fetal information, and dramatic strides have also been made in the accuracy of prenatal diagnosis. Nevertheless, it remains difficult to obtain appropriate information by conventional methods in areas such as fetal electrocardiographic phenomena and central nervous system activity.

Magnetocardiography (MCG) is a technique that utilizes a superconducting quantum interference device (SQUID) for three-dimensional extracorporeal analysis of the minute magnetic fields generated by electrocardiographic phenomena in the heart. MCG has the following features not possessed by electrocardiography (ECG): (1) it enables noncontact measurement; (2) it offers outstanding temporospatial resolution; (3) unlike ECG, which measures scalar quantities, it measures vector quantities, enabling assessment in three dimensions (X, Y, Z); (4) because magnetic permeability is constant, unaffected by fat or neighboring organs, theretus, including a SQUID fluxmeter utilizing liquid helium for measurement and a magnetically shielded room.

As MCG enables noncontact, noninvasive measurement, fetal MCG (FMCG) is regarded as exceptionally useful for the analysis of fetal electrocardiographic phenomena. In recent years, FMCG has also been used in a wide range of clinical applications in the field of prenatal treatment [1-9]. We herein report our use of MCG for the diagnosis of fetal arrhythmias, and to perform an analysis of fetal autonomic nervous system activity.

2. MATERIALS AND METHODS

2.1. Subjects

2.1.1. Diagnosis of Fetal Arrhythmias

We analyzed ten cases of fetal arrhythmia referred to Iwate Medical University Hospital for detailed testing (Table 1).

2.1.2. Assessment of Fetal Autonomic Nervous System Activity

Table 1. Fetal arrhythmia Cases Analyzed by MCG

<table>
<thead>
<tr>
<th>Case</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Premature ventricular contraction (PVC)</td>
<td>4</td>
</tr>
<tr>
<td>Premature atrial contraction (PAC)</td>
<td>2</td>
</tr>
<tr>
<td>Multifocal PVC</td>
<td>1</td>
</tr>
<tr>
<td>Atrial flutter</td>
<td>1</td>
</tr>
<tr>
<td>Ventricular tachycardia (VT)</td>
<td>1</td>
</tr>
<tr>
<td>Complete AV block</td>
<td>1</td>
</tr>
</tbody>
</table>

Study subjects comprised 35 fetuses who underwent normal pregnancy (28-39 gestational weeks) and 12 fetuses...
with intrauterine fetal growth restriction (FGR) (32-37 gestational weeks) (Table 2). In the normal pregnancy group, fetuses were born at term, without any abnormal neurological signs. In the FGR group, ultrasonography was performed by several specialists for all cases who underwent FMCG. All of these cases presented with asymmetrical FGR with weight 10% below normal values; none had complications at birth.

Written informed consent was obtained from all subjects after being briefed about the clinical study, which was approved by the Ethics Committee of the School of Medicine, Iwate Medical University (H14-33, H17-2).

### 2.2. Equipment

In order to obtain FMCG measurements, pregnant volunteers assumed a supine position on a bed and were scanned with a 64-channel MCG sensor (Prototype made by the Joint Research Project for Regional Intensive in Iwate Prefecture; SQUID sensor; Hitachi High-Technology Co., Ltd., Tokyo, Japan) installed in a magnetically shielded room (Fig. 1). The position of the fetus was determined by ultrasonography, using the navel and pubic symphysis as reference coordinates (Fig. 2A, 2B). The magnetic field in the z direction (Bz) adjacent to the body surface was monitored continuously for 5 minutes. A total of two or three measurements were obtained in this manner. As the detected Bz is a summation of signals from fetal and maternal sources, the maternal QRS waveform was subtracted from the detected Bz to derive the actual Bz value. Fetal heart rhythm (approximately 700 beats) was measured for 5 minutes, and the average heart rate was used to derive FMCG data in each case.

### Table 2. Descriptive Characteristics of Normal and Growth Restricted Fetuses (FGR)

<table>
<thead>
<tr>
<th>Item</th>
<th>Normal Fetuses (n = 35) (Max–Min)</th>
<th>FGR Fetuses (n = 12) (Max–Min)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal age (years)</td>
<td>31.7 ± 6.46 (44–20)</td>
<td>30.9 ± 5.79 (42–23)</td>
<td>NS</td>
</tr>
<tr>
<td>Gestational age (weeks)</td>
<td>33.9 ± 3.49 (39–28)</td>
<td>35.2 ± 1.80 (37–32)</td>
<td>NS</td>
</tr>
</tbody>
</table>

Values are represented as the mean ± SD
NS: not significant.

Fig. (1). Monitoring device for magnetocardiography (MCG) incorporating a 64-channel SQUID apparatus in a magnetically shielded room.
Fig. (2). Method for fetal magnetocardiography (FMCG). Position of the fetus was referenced using standard coordinates based on the navel region and pubic symphysis (A). Detected magnetic field signals, which comprised signals derived from both the mother and fetus, were subtracted from the maternally derived QRS waveform (B). When performing FMCG, a total of 300-500 heartbeats detected per determination were summated to yield mean values (C).

Fig. (3). Determination of PQ, QRS and QT intervals by differentiation. In performing FMCG, a total of 300-500 heartbeats detected per determination were summated to yield mean values. The initial and termination points of the PQ, QRS and T wave were defined based on the first derivative of dF/dt (Fig. 3).

CVRR was calculated as follows:

\[
CV_{RR} = \frac{SD}{M} \times 100\%
\]

where \(n\) and \(Di\) represent the number of R–R intervals and the mean of approximately 700 R–R intervals, respectively, and \(M\) represents the total mean of the respective \(Di\).

The power spectrum in the frequency domain was derived from frequency-field components using the maximum entropy method of fetal heart rate variability. Based on frequency analysis, the ranges of the LF and HF domains were defined as 0.01-0.15 Hz and 0.15-0.4 Hz, respectively.
Fig. (4). Representative FMCG recordings in Case 1
Maternal sinus rhythm: ↓
Fetal sinus rhythm: ↓
Premature ventricular contraction (PVC): ↓
FHR: 136 bpm
PVC: 194 times/5 min
R–R interval: 438 ms
Standard deviation: 71.4
Coefficient of variation: 16.3%

Fig. (5). Representative FMCG recordings in Case 2
Maternal sinus rhythm: ↓
Fetal sinus rhythm: ↓
Premature atrial contraction (PAC): ↓
Heart rate: 140 bpm
R–R interval: 428 ms
Standard deviation: 15.4
Coefficient of variation: 3.6%
Fig. (6). Representative FMCG recordings in Case 3. Each non-averaged FMCG channel represents wide QRS tachycardia (torsades de pointes), ventricular asystole and sinus rhythm at 28 weeks 3 days gestation.

The respective power values were derived to yield the LF/HF ratio. Note that the LF/HF ratio is taken as sympathetic activity of the fetal autonomic nervous system (ANS) [10, 11].

2.3. Statistical Analysis

Data were analyzed using StatView for Windows Ver. 5.0 (SAS Institute Inc., Cary, NC). The relationships among CVRR, LF/HF and gestational age in each group were analyzed by linear regression, while inter-group changes in CVRR and LF/HF over the gestational period in each group were verified by one-way ANOVA. Changes in CVRR and LF/HF over the gestational period between normal pregnancy and the FGR group were analyzed by two-way ANOVA.

3. RESULTS

3.1. Prenatal Diagnosis of Fetal Arrhythmias

We describe below three representative cases out of ten, in which FMCG was used to analyze fetal arrhythmias.

Fetal arrhythmia case 1: Premature ventricular contraction (PVC)

The mother was urgently transported to our hospital at 39 weeks 4 days gestation due to fetal bradyarrhythmia. FMCG indicated a prenatal diagnosis of PVC, as shown in Fig. (4). A female infant (birth weight, 3480 g) was born by normal vaginal delivery at 41 weeks 0 days gestation. The diagnosis of PVC was confirmed postnatally by ECG.

Fetal arrhythmia case 2: Premature atrial contraction (PAC)

The mother was transported to our hospital at 27 weeks 4 days gestation due to fetal arrhythmia. FMCG indicated a prenatal diagnosis of PAC, as shown in Fig. (5). A male infant (birth weight, 2576 g) was born by normal vaginal delivery at 38 weeks 6 days gestation, and the arrhythmia resolved postnatally.

Fetal arrhythmia case 3: Polymorphic ventricular tachycardia

The mother was urgently transported to our hospital at 24 weeks 4 days gestation due to persistent fetal bradycardia and fetal ascites. FMCG findings at 28 weeks 1 day gestation, revealed multiple episodes of non-sustained polymorphic VT and ventricular asystole (Fig. 6). The time intervals for QRS and QTc (using Bazzet’s correction) were determined by signal-averaging FMCG during sinus rhythm at an optimal channel setting (channel 51). The QRS interval during a signal-averaged sinus rhythm at channel 51 was 90 ms, and QTc was 491 ms.

Fig. (7). Signal-averaged representative MCG recordings in Case 3. Time interval of QRS and QTc (using Bazzet’s correction) was determined during signal-averaged sinus rhythm on channel 51. QRS interval during signal-averaged sinus rhythm at channel 51 was 90 ms, and QTc was 491 ms.

The mother was urgently transported to our hospital at 24 weeks 4 days gestation due to persistent fetal bradycardia and fetal ascites. FMCG findings at 28 weeks 1 day gestation, revealed multiple episodes of non-sustained polymorphic VT and ventricular asystole (Fig. 6). The time intervals for QRS and QTc (using Bazzet’s correction) were determined by signal-averaging FMCG during sinus rhythm at an optimal channel setting (channel 51). The QRS interval during a signal-averaged sinus rhythm at channel 51 was 90 ms and QTc was 491 ms (Fig. 7). At the instant of diagnosing
non-sustained polymorphic VT, MgSO₄ was administered to avoid life-threatening arrhythmia. Administration of a β₂-stimulant (typically employed for the treatment of threatened premature delivery) was avoided. There was no direct evidence for the effectiveness of avoiding QT prolongation using Mg SO₄ by FMCG; this baby was successfully delivered at term. At 37 weeks 1 day gestation, a female infant (birth weight, 2,748 g) was delivered by cesarean section. Standard electrocardiography (ECG) on the day of the birth confirmed non-sustained polymorphic VT, followed by sinus rhythm with 2:1 atrioventricular (AV) block, left bundle branch block (LBBB) and QT prolongation (Fig. 8). Pacemaker treatment was initiated immediately after diagnosis [9].

3.2. Fetal Autonomic Nervous System Activity (Comparison of Normal Pregnancy and FGR)

The normal pregnancy group was divided into three groups for classifying one-way ANOVA of CVRR and LF/HF, as follows: Group A, 28-31 weeks gestation (8th month of pregnancy); Group B, 32-35 weeks gestation (9th month of pregnancy); and Group C, 36-40 weeks gestation (10th month of pregnancy).

The value of CVRR in normal pregnancy showed a slightly elevated trend with gestational age ($y = 1.77 + 0.10x; r = 0.32$). In contrast, the value of CVRR in the FGR group showed no such trend (Fig. 9). Inter-group changes in
CV_{RR} over the gestational age periods in normal pregnancy showed no statistical differences on one-way ANOVA [7, 8] (Fig. 10).

The value for LF/HF in both the normal pregnancy group and the FGR group increased with gestational age ($y = 0.19 + 0.04x$, $r = 0.49$, and $y = 0.16 + 0.04x$, $r = 0.23$, respectively) (Fig. 11). Inter-group changes in LF/HF in the normal group increased significantly with gestation period (one-way ANOVA: $P = 0.003$) [7, 8] (Fig. 12). There were no significant differences in inter-group changes in LF/HF ratio between normal pregnancy and FGR.

4. DISCUSSION

Recent advances in medical technology and techniques, such as ultrasonography and cardiotocography, have enabled various fetal parameters in the field of perinatal medicine to
activities. safe and non-invasive method for monitoring fetal cardiac in both fetuses and adults. FMCG is an extremely possible for the device to perform a 3-dimensional analysis channel MCG [12, 13]. The special features of MCG make it diagnostic accuracy. In the present study, we developed an FMCG approach by modifying our recently developed 64-channel MCG [12, 13]. The special features of MCG make it the heart in both fetuses and adults. FMCG is an extremely safe and non-invasive method for monitoring fetal cardiac activities.

To date, numerous studies have used FMCG to analyze fetal arrhythmias [5, 6, 14-16]. In the cases we have analyzed to date, particularly fetal atrial arrhythmia case 3, it would have been extremely difficult to reach an accurate diagnosis using conventional testing methods, meaning that it might not have been possible to select appropriate treatment strategies. FMCG has been extremely useful for the accurate diagnosis of fetal arrhythmia and its effective monitoring during pregnancy, enabling these fetuses to be managed appropriately up to 37 weeks gestation. FMCG has also enabled the appropriate planning of birth timing, delivery method and postnatal treatment [9].

In addition to fetal structural anomalies, there are many other aspects of contemporary perinatal medicine in which fetal functional assessment is required, such as intrauterine assessment of fetuses with FGR, and analysis of the cause and timing of onset of cerebral palsy. To assess fetal ANS function, Shields and Schifrin evaluated fetal heart rate variability derived from fetal cardiotocography and respiratory movements [17]. More than 90% of fetal asphyxia cases were detected by abnormal heart rate patterns using cardiotocography. Thus, cardiotocography is an indispensable tool that is routinely employed in clinical obstetrics; however, even when abnormal heart rate patterns are detected, the combined use of ultrasonic Doppler and biophysical profile analysis does not improve the ability to identify undiagnosed cases of asphyxia. These conventional methods are yet to objectively and reliably evaluate functional development of the fetal ANS; they are also unable to consistently achieve prenatal diagnosis of conditions that result from abnormal fetal ANS development, such as cerebral palsy. As a result, unnecessary obstetric interventions are encountered, and the rate of cesarean section continues to increase without any decrease in the incidence of fetal central nervous system impairments, particularly cerebral palsy. This problem highlights the need for novel approaches to prenatal diagnosis [18, 19].

MCG can thus be used for analysis of fetal heart rate variability, enabling further improvements to the accuracy of assessments of fetal wellbeing. Although analyses of heart rate variability have been attempted using FMCG, little has been established [20, 21]. To advance the development of this method, we undertook the following studies: (1) elucidation of the developmental stages of fetal ANS over a period of 39 weeks; and (2) comparison of FMCG findings between normal pregnancy and FGR groups. In FGR cases, the difference in fetal size and other obstetric risks are greater, and the correlation decreases when compared with the normal pregnancy group; that is, the heart rate coordination system is non-versatile and highly susceptible to stress [22, 23]. Therefore, it is critical to differentiate on the grounds of perinatal management whether a fetus has low body weight alone, or whether it also has endogenous functional issues.

According to a previous study [7, 8], the results of attempted measurements of CVRR, a value that reflects parasympathetic nervous system (PSN) activity [24, 25], indicated that CVRR values exhibited a slightly increasing trend with gestational age in the normal pregnancy group. In addition, we defined the value of the LF/HF ratio as sympathetic nervous system (SNS) activity or the balancing factor between SNS and PNS activities [26]. The LF/HF ratio showed a clear increase with gestational age in the normal pregnancy group [7, 8]; fetal ANS function is known to develop as gestation progresses [26]. These results are consistent with ultrasound analyses of the fetal mouth movement interval and eye-movement phase patterns, in which major changes occur at around gestational weeks 28-33 [23]. This evidence from earlier studies is consistent with the results of the present study. Our results revealed that the maturation process, particularly in SNS activity or the balancing factor between SNS and PNS activities, changes dramatically from 28-39 weeks gestation. Furthermore, for the fetus, therefore, it is very important to avoid preterm delivery, not only in terms of body size and organic maturation, but also for the functional development of ANS.

A previous frequency analysis using FMCG indicated decreased complexity and increased periodicity of the LF and HF ranges in FGR cases [21]. In another previous study, the value of the LF/HF ratio in the IUGR group tended to increase with gestational age; however, the value of CVRR did not show a clear trend. This finding may depend on growth restriction or heterogeneity in terms of etiology and severity in FGR cases [8, 27]. Further investigation of FGR cases, along with detailed analyses of patient background, is therefore required. The development pattern of ANS in the fetal period may thus become an important index for prenatal management in the near future.

![Fig. (12)](image) Inter-group changes in the low frequency/high frequency (LH/HF) ratio during normal pregnancy. Group A, 28-31 weeks gestation; Group B, 32-35 weeks gestation; and Group C, 36-40 weeks gestation.
CONCLUSION

MCG could be used for analysis of both fetal arrhythmia and fetal heart rate variability. MCG thus enables the acquisition of fetal information that could not be obtained by conventional diagnostic techniques, such as ultrasonography and cardiotocography, and represents an extremely useful diagnostic technique.

CONFLICT OF INTEREST

None declared.

ACKNOWLEDGEMENTS

This study was supported by the Budding Scientific Research Grant-in-Aid #17591753 from the Ministry of Education, Science, and Culture of Japan; Joint Research Project for Regional Intensive in Iwate Prefecture; Dreamland Iwate Strategic Research Promotion Project (2005); the Keiryokai for Regional Intensive in Iwate Prefecture; Dreamland Iwate Search Grant-in-Aid #17591753 from the Ministry of Education.

REFERENCES


© Fukushima et al.; Licensee Bentham Open.

This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.